4889.T Stock - Renascience Inc.
Unlock GoAI Insights for 4889.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $132.69M | $194.16M | $100.55M | $139.33M | $209.80M |
| Gross Profit | $128.95M | $165.64M | $100.30M | $77.60M | $179.82M |
| Gross Margin | 97.2% | 85.3% | 99.8% | 55.7% | 85.7% |
| Operating Income | $-178,828,000 | $-252,335,000 | $-333,870,000 | $-210,839,000 | $-86,125,000 |
| Net Income | $113.43M | $-258,335,000 | $-335,797,000 | $-254,292,000 | $-100,054,000 |
| Net Margin | 85.5% | -133.0% | -334.0% | -182.5% | -47.7% |
| EPS | $8.92 | $-20.32 | $-26.42 | $-22.33 | $-10.19 |
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4889.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-6.68 | — | — |
Q3 2025 | Aug 13, 2025 | — | — | — | — |
Q2 2025 | May 14, 2025 | — | $-3.20 | — | — |
Q1 2025 | Feb 13, 2025 | — | $17.78 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-4.41 | — | — |
Q3 2024 | Aug 8, 2024 | — | $-1.26 | — | — |
Q2 2024 | May 9, 2024 | — | $-2.82 | — | — |
Q1 2024 | Feb 8, 2024 | — | $-10.00 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-7.67 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.17 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-8.59 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-5.74 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-7.10 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-7.10 | — | — |
Q2 2022 | May 12, 2022 | — | — | — | — |
Latest News
Frequently Asked Questions about 4889.T
What is 4889.T's current stock price?
What is the analyst price target for 4889.T?
What sector is Renascience Inc. in?
What is 4889.T's market cap?
Does 4889.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4889.T for comparison